Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Asian Stocks Edge Higher as Tech Recovers, U.S. Economic Uncertainty Caps Gains 
Chinese Robotaxi Stocks Rally as Tesla Boosts Autonomous Driving Optimism 
China’s November Economic Data Signals Slowing Industrial Output and Weak Consumer Demand 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data 
Japan PMI Data Signals Manufacturing Stabilization as Services Continue to Drive Growth 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Bank of Korea Downplays Liquidity’s Role in Weak Won and Housing Price Surge 
Asian Currencies Slip as Dollar Strengthens; Indian Rupee Rebounds on Intervention Hopes 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Celltrion’s antibody treatment for COVID-19 has been granted approval for emergency use in Peru. The South Korean pharmaceutical company announced on Monday, Nov. 22, that the Peruvian authorities approved its Regkirona treatment for emergency application on adult patients with COVID-19.
According to Yonhap News Agency, Peru authorized Celltrion’s antibody treatment for emergency use based on recent results of phase three clinical study of the drug. The study was for attaining more comprehensive results for Regkirona’s effectiveness and safety, and since the results were good, it was approved.
The antibody treatment is being administered to patients in the form of an intravenous injection. It was said to be directly injected for 60 minutes.
Peru is the latest country to issue approval on Celltrion’s drug for treating COVID-19. It has already won approval from other states, such as Brazil and Indonesia, for emergency application. In its home base, which is South Korea, Regkirona has already won the authorities’ drug safety conditional approval in February.
One of the best things about the new drug is that it can lower the risk of COVID-19’s progress to severe levels. What’s more, Celltrion previously stated that its antibody treatment could also reduce the recovery time of patients.
Celltrion’s Regkirona is also South Korea’s very first COVID-19 treatment and it secured approval from Peru just a week after receiving marketing approval from the European Commission. The monoclonal antibody treatment was given the go-ahead last week.
Today’s achievement, coupled with Committee for Medicinal Products for Human Use (CHMP) positive opinion for Regdanvimab, underscores our ongoing commitment to addressing the world’s greatest health challenges,” Celltrion Healthcare’s head of medical and marketing, Dr. HoUng Kim, Ph.D., said in a press release. “Typically, the recommendations from the CHMP are passed on to the EC for rapid legally binding decisions within a month or two, however, given the unprecedented times, we have received the EC approval within a day.”
Meanwhile, the medical and marketing chief added that they are currently in talks with contractors and governments in 30 countries more across Asia, Europe, and Latin America. Celltrion said it would continue to work to make sure that COVID-19 patients worldwide will have access to safe and effective treatment.
